Cargando…

LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

BACKGROUND: Neoadjuvant chemotherapy (NAC) is an important treatment for locally advanced breast cancer (LABC). However, there are no effective biomarkers to predict the efficacy. Therefore, there is an urgent need for new biomarkers to predict the response of LABC to NAC. LncRNA BCAR4 has been dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Feng-Jiao, Li, Yi, Xu, Meng-Xi, Zhou, Tie, Wu, Shun, Hu, Kang, Li, Yan, Sun, Su-Hong, Luo, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673519/
https://www.ncbi.nlm.nih.gov/pubmed/34151842
http://dx.doi.org/10.3233/CBM-210048
_version_ 1784615468576800768
author Gan, Feng-Jiao
Li, Yi
Xu, Meng-Xi
Zhou, Tie
Wu, Shun
Hu, Kang
Li, Yan
Sun, Su-Hong
Luo, Qing
author_facet Gan, Feng-Jiao
Li, Yi
Xu, Meng-Xi
Zhou, Tie
Wu, Shun
Hu, Kang
Li, Yan
Sun, Su-Hong
Luo, Qing
author_sort Gan, Feng-Jiao
collection PubMed
description BACKGROUND: Neoadjuvant chemotherapy (NAC) is an important treatment for locally advanced breast cancer (LABC). However, there are no effective biomarkers to predict the efficacy. Therefore, there is an urgent need for new biomarkers to predict the response of LABC to NAC. LncRNA BCAR4 has been detected in a variety of malignant tumor tissues and used as a new biomarker for diagnosis and prognosis. However, LncRNA BCAR4 predicts the response of LABC to NAC is unclear. OBJECTIVE: Explore the predictive effect of LncRNA BCAR4 on the efficacy of NAC for LABC in three different evaluation systems. METHODS: First, the TCGA database was used to analyze the expression of LncRNA BCAR4 in 33 kinds of malignant tumors, and further explore its expression in breast cancer and its impact on the survival and prognosis of breast cancer. Furthermore, quantitative methods were used to measure the expression level of LncRNA BCAR4 in cancer tissues of 48 LABC patients, and the correlation between LncRNA BCAR4 and clinicopathological status and response to NAC under the evaluation system of 3, RECIST1.1, Miller-Payne (MP) score and whether it reaches pCR,was analyzed. RESULTS: TCGA data analysis found that LncRNA is highly expressed in a variety of malignant tumor tissues, including breast cancer. And relatively low expression, the shorter the overall survival time of high expression patients. The high expression of LncRNA BCAR4 is related to the size of the tumor, and there are differences in expression between stage I and other stages, but there is no obvious correlation with the positive lymph node and hormone receptor status. Among the three evaluation systems, only in the RECIST 1.1 evaluation system LncRNA BCAR4 has a predictive effect on NAC for LABC. The expression of LncRNA BCAR4 has no significant correlation with clinical stage, Ki-67% and hormone receptor status, and has no significant correlation with whether patients with locally advanced breast cancer obtain pCR during neoadjuvant chemotherapy. CONCLUSION: LncRNA BCAR4 is highly expressed in LABC tissues and may be an effective marker for predicting the efficacy of NAC for LABC.
format Online
Article
Text
id pubmed-8673519
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-86735192021-12-29 LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Gan, Feng-Jiao Li, Yi Xu, Meng-Xi Zhou, Tie Wu, Shun Hu, Kang Li, Yan Sun, Su-Hong Luo, Qing Cancer Biomark Research Article BACKGROUND: Neoadjuvant chemotherapy (NAC) is an important treatment for locally advanced breast cancer (LABC). However, there are no effective biomarkers to predict the efficacy. Therefore, there is an urgent need for new biomarkers to predict the response of LABC to NAC. LncRNA BCAR4 has been detected in a variety of malignant tumor tissues and used as a new biomarker for diagnosis and prognosis. However, LncRNA BCAR4 predicts the response of LABC to NAC is unclear. OBJECTIVE: Explore the predictive effect of LncRNA BCAR4 on the efficacy of NAC for LABC in three different evaluation systems. METHODS: First, the TCGA database was used to analyze the expression of LncRNA BCAR4 in 33 kinds of malignant tumors, and further explore its expression in breast cancer and its impact on the survival and prognosis of breast cancer. Furthermore, quantitative methods were used to measure the expression level of LncRNA BCAR4 in cancer tissues of 48 LABC patients, and the correlation between LncRNA BCAR4 and clinicopathological status and response to NAC under the evaluation system of 3, RECIST1.1, Miller-Payne (MP) score and whether it reaches pCR,was analyzed. RESULTS: TCGA data analysis found that LncRNA is highly expressed in a variety of malignant tumor tissues, including breast cancer. And relatively low expression, the shorter the overall survival time of high expression patients. The high expression of LncRNA BCAR4 is related to the size of the tumor, and there are differences in expression between stage I and other stages, but there is no obvious correlation with the positive lymph node and hormone receptor status. Among the three evaluation systems, only in the RECIST 1.1 evaluation system LncRNA BCAR4 has a predictive effect on NAC for LABC. The expression of LncRNA BCAR4 has no significant correlation with clinical stage, Ki-67% and hormone receptor status, and has no significant correlation with whether patients with locally advanced breast cancer obtain pCR during neoadjuvant chemotherapy. CONCLUSION: LncRNA BCAR4 is highly expressed in LABC tissues and may be an effective marker for predicting the efficacy of NAC for LABC. IOS Press 2021-11-10 /pmc/articles/PMC8673519/ /pubmed/34151842 http://dx.doi.org/10.3233/CBM-210048 Text en © 2021 – The authors. Published by IOS Press. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gan, Feng-Jiao
Li, Yi
Xu, Meng-Xi
Zhou, Tie
Wu, Shun
Hu, Kang
Li, Yan
Sun, Su-Hong
Luo, Qing
LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title_full LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title_fullStr LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title_full_unstemmed LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title_short LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
title_sort lncrna bcar4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673519/
https://www.ncbi.nlm.nih.gov/pubmed/34151842
http://dx.doi.org/10.3233/CBM-210048
work_keys_str_mv AT ganfengjiao lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT liyi lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT xumengxi lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT zhoutie lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT wushun lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT hukang lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT liyan lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT sunsuhong lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer
AT luoqing lncrnabcar4expressionpredictstheclinicalresponsetoneoadjuvantchemotherapyinpatientswithlocallyadvancedbreastcancer